Harrow, Inc. (NASDAQ:HROW) Shares Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC increased its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 23.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 314,881 shares of the company's stock after acquiring an additional 59,019 shares during the period. Rice Hall James & Associates LLC owned approximately 0.89% of Harrow worth $14,157,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of HROW. nVerses Capital LLC acquired a new stake in shares of Harrow in the 2nd quarter worth approximately $33,000. Allspring Global Investments Holdings LLC lifted its stake in Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company's stock valued at $44,000 after buying an additional 2,048 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after buying an additional 227 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Harrow in the 1st quarter valued at approximately $185,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Harrow by 6.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company's stock valued at $221,000 after buying an additional 1,033 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Trading Up 1.3 %

Shares of Harrow stock traded up $0.58 during trading hours on Friday, reaching $45.64. 256,474 shares of the company's stock were exchanged, compared to its average volume of 496,497. Harrow, Inc. has a 52-week low of $7.60 and a 52-week high of $59.23. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -47.81 and a beta of 0.75. The company has a fifty day moving average of $46.39 and a 200-day moving average of $29.47. The company has a current ratio of 2.60, a quick ratio of 2.43 and a debt-to-equity ratio of 3.18.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.12. The company had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. Sell-side analysts forecast that Harrow, Inc. will post 0.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HROW. B. Riley reaffirmed a "buy" rating and issued a $50.00 target price on shares of Harrow in a research note on Thursday, August 29th. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Finally, Craig Hallum increased their price target on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, October 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.